HIV co-receptor inhibitors as novel class of anti-HIV drugs

被引：31

作者：

Schols, Dominique ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ANTIVIRAL RESEARCH | 2006年 / 71卷 / 2-3期

关键词：

CCR5; CXCR4; antagonist; HIV; chemokine receptor; gp120; envelope; HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CXCR4; SMALL-MOLECULE INHIBITOR; HUMAN LYMPHOID-TISSUE; INFECTION IN-VITRO; TYPE-1; REPLICATION; CCR5; ANTAGONIST; HIGHLY POTENT; TROPIC HIV-1; SELECTIVE-INHIBITION;

D O I：

10.1016/j.antiviral.2006.04.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Entry inhibitors constitute a new class of drugs to treat infection by human immunodeficiency virus type 1 (HIV-1). The first member of this class, enfuvirtide, previously known as T-20 and targeting gp41, has now been licensed for therapeutic use. Several other entry inhibitors are in various stages of pre-clinical or clinical development. In this review we focus on the chemokine receptor inhibitors targeting CCR5 and CXCR4 that are the main HIV co-receptors for viral entry. (c) 2006 Elsevier B.V. All rights reserved.

引用

页码：216 / 226

页数：11

共 97 条

[1] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].

Alkhatib, G ;

Combadiere, C ;

Broder, CC ;

Feng, Y ;

Kennedy, PE ;

Murphy, PM ;

Berger, EA .

SCIENCE, 1996, 272 (5270) :1955-1958

[2] The LD78β isoform of MIP-1α is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages [J].

Aquaro, S ;

Menten, P ;

Struyf, S ;

Proost, P ;

Van Damme, J ;

De Clercq, E ;

Schols, D .

JOURNAL OF VIROLOGY, 2001, 75 (09) :4402-4406

[3] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure [J].

Arakaki, R ;

Tamamura, H ;

Premanathan, M ;

Kanbara, K ;

Ramanan, S ;

Mochizuki, K ;

Baba, M ;

Fujii, N ;

Nakashima, H .

JOURNAL OF VIROLOGY, 1999, 73 (02) :1719-1723

[4] HIV blocked by chemokine antagonist [J].

ArenzanaSeisdedos, F ;

Virelizier, JL ;

Rousset, D ;

ClarkLewis, I ;

Loetscher, P ;

Moser, B ;

Baggiolini, M .

NATURE, 1996, 383 (6599) :400-400

[5] TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans [J].

Baba, M ;

Takashima, K ;

Miyake, H ;

Kanzaki, N ;

Teshima, K ;

Wang, X ;

Shiraishi, M ;

Iizawa, Y .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4584-4591

[6] Chemokines and leukocyte traffic [J].

Baggiolini, M .

NATURE, 1998, 392 (6676) :565-568

[7]

BAHA M, 1999, P NATL ACAD SCI USA, V96, P5698

[8] A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains [J].

Berson, JF ;

Long, D ;

Doranz, BJ ;

Rucker, J ;

Jirik, FR ;

Doms, RW .

JOURNAL OF VIROLOGY, 1996, 70 (09) :6288-6295

[9] The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J].

Bleul, CC ;

Farzan, M ;

Choe, H ;

Parolin, C ;

ClarkLewis, I ;

Sodroski, J ;

Springer, TA .

NATURE, 1996, 382 (6594) :829-833

[10] Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-8 replication by antagonism of the chemokine receptor CXCR4 [J].

Bridger, GJ ;

Skerlj, RT ;

Padmanabhan, S ;

Martellucci, SA ;

Henson, GW ;

Struyf, S ;

Witvrouw, M ;

Schols, D ;

De Clercq, E .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (19) :3971-3981

← 1 2 3 4 5 6 7 8 9 10 →